Advertisement

In Vitro Modulation of Multidrug Resistance by BIBW22BS in Blasts of De Novo or Relapsed or Persistent AML

  • J. Schröder
  • M. Esteban
  • S. Kasimir-Bauer
  • U. Bamberger
  • A. Heckel
  • M. E. Scheulen
  • S. Seeber
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 37)

Abstract

Drug resistance to chemotherapy is an important factor of treatment failure in acute myeloid leukemia (AML). One type of resistance, the multidrug resistance (MDR), can develop after exposure to certain natural chemotherapeutic agents such as vinca alkaloids, anthracyclines, actinomycin D, and epipodophyllotoxins (Biedler & Riehm 1970). MDR is associated with overexpression of a 170 kDa membrane glycoprotein (P170), which is encoded by the mdr1 gene located on the long arm of chromosome 7 (Bradley et al. 1988). Membrane transport studies have shown that calcium channel blocking agents such as verapamil (VER) inhibit drug efflux by direct binding to P170 causing increased intracellular drug accumulation (Willingham et al. 1986; Safa et al. 1987). Recent clinical studies have indicated that MDR is induced by treatment with anthracyclines and vinca alkaloids in several hematologic malignancies (te Boekhorst et al. 1993). Thus, the expression of mdr1 is detected in about 50% of patients with pretreated AML, in contrast to only 20% of patients with de novo AML (Marie et al. 1991). Patients with mdr1 gene expression had a significantly shorter overall survival compared with the mdr1-negative group (Pirker et al. 1991).

Keywords

Acute Myeloid Leukemia Multidrug Resistance Vinca Alkaloid Nucleoside Transport Acute Myeloid Leukemia Blast 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Beck WT, Mueller TJ, Tanzer LR (1979) Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblasts. Cancer Res 39: 2070–2076PubMedGoogle Scholar
  2. 2.
    Biedler JL, Riehm H (1970) Cellular resistance to actinomycin D in Chinese hamster cells in vitro: Cross resistance, radioautographic and cytogenetic studies. Cancer Res 30: 1174–1184PubMedGoogle Scholar
  3. 3.
    Bradley G, Jurunka PF, Ling V (1988) Mechanism of multidrug resistance. Biochim Biophys Acta 948: 87–128PubMedGoogle Scholar
  4. 4.
    Chen HX, Bamberger U, Heckel A, Guo X, Cheng YC (1993) BIBW 22, a dipyridamole analogue, acts as a bifunctional modulator on tumor cells by influencing both P-glycoprotein and nucleoside transport. Cancer Res 53: 1974–1977PubMedGoogle Scholar
  5. 5.
    Kaye SB (1990) Reversal of multidrug resistance. Cancer Treat Rev 17 (Suppl A): 37–43PubMedCrossRefGoogle Scholar
  6. 6.
    Marie J-P, Zittoun R, Sikic BI (1991) Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 78: 586–592PubMedGoogle Scholar
  7. 7.
    Meyers MB, Rittmann-Grauer L, O’Brien JP, Safa SR (1989) Characterization of monoclonal antibodies recognizing a Mr 180,000 P-glycoprotein: Differential expression of the Mr 180,000 and Mr 170,000 P-glycoprotein in multidrug-resistant human tumor cells. Cancer Res 49: 3209–3214PubMedGoogle Scholar
  8. 8.
    Pirker R, Wallner J, Geissler K, Linkesch W, Haas OA, Bettelheim P, Hopfner M, Scherrer R, Valent P, Havelec L, Ludwig H, Lechner K (1991) MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 83: 708–712PubMedCrossRefGoogle Scholar
  9. 9.
    Safa AR, Glover CJ, Sewell JL, Meyers MB, Biedler JL, Felsted RL (1987) Identification of the multidrug resistance-related membrane glycoprotein as an acceptor for calcium channel blockers. J Biol Chem 262: 7884–7888PubMedGoogle Scholar
  10. 10.
    te Boekhorst PAW, de Leeuw K, Schoester M, Wittebol S, Nooter K, Hagemeijer A, Löwenberg B, Sonneveld P (1993) Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells. Blood 82: 3157–3162Google Scholar
  11. 11.
    Willingham MC, Cornwell MM, Cardarelli CO, Gottesman MM, Pastan I (1986) Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and -sensitive B cells: effects of verapamil and other drugs. Cancer Res 46: 5941–5946PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1996

Authors and Affiliations

  • J. Schröder
    • 1
  • M. Esteban
    • 1
  • S. Kasimir-Bauer
    • 1
  • U. Bamberger
    • 2
  • A. Heckel
    • 2
  • M. E. Scheulen
    • 1
  • S. Seeber
    • 1
  1. 1.Innere Klinik und Poliklinik (Tumorforschung),Westdeutsches TumorzentrumUniversitätsklinikum EssenEssenGermany
  2. 2.Dr. Karl Thomae GmbHBiberach/RißGermany

Personalised recommendations